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Abstract
Background: Pharmacological management of chronic neuropathic pain (CNP) still represents a major clinical
challenge. Collective harnessing of both the scientific evidence base and clinical experience (of clinicians and
patients) can play a key role in informing treatment pathways and contribute to the debate on specific treat-
ments (e.g., cannabinoids). A group of expert clinicians (pain specialists and psychiatrists), scientists, and patient
representatives convened to assess the relative benefit–safety balance of 12 pharmacological treatments, includ-
ing orally administered cannabinoids/cannabis-based medicinal products, for the treatment of CNP in adults.
Methods: A decision conference provided the process of creating a multicriteria decision analysis (MCDA)
model, in which the group collectively scored the drugs on 17 effect criteria relevant to benefits and safety
and then weighted the criteria for their clinical relevance.
Findings: Cannabis-based medicinal products consisting of tetrahydrocannabinol/cannabidiol (THC/CBD), in a
1:1 ratio, achieved the highest overall score, 79 (out of 100), followed by CBD dominant at 75, then THC dominant
at 72. Duloxetine and the gabapentinoids scored in the 60s, amitriptyline, tramadol, and ibuprofen in the 50s,
methadone and oxycodone in the 40s, and morphine and fentanyl in the 30s. Sensitivity analyses showed
that even if the pain reduction and quality-of-life scores for THC/CBD and THC are halved, their benefit–safety
balances remain better than those of the noncannabinoid drugs.
Interpretation: The benefit–safety profiles for cannabinoids were higher than for other commonly used med-
ications for CNP largely because they contribute more to quality of life and have a more favorable side effect
profile. The results also reflect the shortcomings of alternative pharmacological treatments with respect to safety
and mitigation of neuropathic pain symptoms. Further high-quality clinical trials and systematic comprehensive
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capture of clinical experience with cannabinoids is warranted. These results demonstrate once again the com-
plexity and multimodal mechanisms underlying the clinical experience and impact of chronic pain.
Keywords: neuropathic pain; analgesics; cannabis-based medical products; CBMP; multicriteria decision analysis;
MCDA
Introduction
Cannabis-based medical products (CBMPs) are now ap-
proved in > 20 countries and so accessible to hundreds of
millions of patients.1,2 But in some countries, notably the
United Kingdom, there is very limited prescribing.1,2
Reasons for this are varied and complex, including con-
siderable medicolegal and bureaucratic hurdles,2,3 but
they also reflect a concern by the medical profession
that the randomized control trial (RCT) evidence base
for medical cannabis is limited and, for many of its pos-
sible indications, inconclusive. This attitude is opposite
to that of many patient testimonies (both in the United
Kingdom and in other countries) where medical canna-
bis is seen as an important addition to their treatment
(UPA 2018). Similarly, clinicians with considerable prac-
tical experience with use of cannabis, including for pain
management, also see this as an important and major ad-
dition to their armamentarium.4,5 The Centre for Medi-
cal Cannabis (CMC) estimates that in the United
Kingdom more than one million patients are using can-
nabis,6 and almost all of them are obtaining it illegally,
which presents them with significant legal and product
quality risks.2 Moreover, these patients are less likely to
involve their health care specialist in the process and,
therefore, manage their own treatment unsupervised.
Surveys highlight that pain is one of the conditions pa-
tients most commonly treated with medical cannabis6,7
and a review by the National Academies of Sciences,
Engineering, and Medicine (NASEM) in 2017 found
the evidence base for chronic pain to be ‘‘substantial.’’8
However, conclusions of recent meta-analyses and sys-
tematic reviews on the use of cannabinoids, cannabis
and cannabis-based medicines to treat chronic neuro-
pathic pain (CNP) have ranged from weakly positive
to inconclusive or negative.9–15 These differing con-
clusions may be the result of including different trial de-
signs, different standards to evaluate the quality of
evidence, and different weighting of the outcomes of
efficacy, tolerability, and safety.16,17 Thus, systematic re-
views examining the same studies often arrived at differ-
ent conclusions and recommendations.18 The scientific
literature examining the efficacy of cannabinoids, canna-
bis, and cannabis-based medicines for CNP is, therefore,
still developing. An expert Task Force of the European
Pain Federation recently published a position article
that concluded that the quantity and quality of evidence
are such that cannabis-based medicines may be reason-
ably considered for CNP. For all other chronic pain con-
ditions (cancer, non-neuropathic noncancer pain), the
use of cannabis-based medicines should be regarded as
an individual therapeutic trial.19 Recent RCTs examining
the efficacy of cannabinoids, cannabis, and cannabis-
based medicines for CNP are shown in Appendix
Table A1. This study focuses exclusively on this area to
narrow down the complexity of chronic pain.
Available data to date suggest that the use of canna-
binoids for chronic pain is relatively safe, with little
evidence for the increase of risk for experiencing seri-
ous adverse events, although nonserious adverse events
may be common in the short-term period after use.20,21
Notably, despite the rapidly increasing multitude of
patients, there has never been an overdose fatality di-
rectly attributed to cannabis use reported in medical
literature. As many patients with chronic pain often
suffer from multiple comorbidities and physical dis-
ability, and considering the numerous safety concerns
of current pain pharmacotherapy,22–24 careful consid-
eration of the safety profile is of crucial importance
and improved harms assessment and reporting are
needed in cannabinoid pain trials.25
This study was designed to explore the evidence base
for the clinical utility of orally administered CBMPs
(including cannabis extracts and cannabis-based med-
icines such as nabiximols [Sativex is approved in 30
countries but not marketed in each] dronabinol, and
nabilone) for management of CNP in adults by creating
a multicriteria decision analysis (MCDA) model that
compares these cannabinoid formulations with other
drugs. The results of this modeling can provide pre-
scribers and others with an updated viewpoint incor-
porating the current state of scientific knowledge as
well as the cumulative clinical experience regarding the
use of orally administered CBMPs for CNP in adults.
MCDA models about drugs often compare a single
drug, or one drug at different doses, with a placebo
as an approach for determining the extent to which
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benefits exceed risks.26,27 A recent trend is to compare
one drug(s) to other drugs for the same medical condi-
tion.28,29 The rationale for this is that drugs for a given
medical condition differ in their benefit–safety profiles,
so making those profiles explicit and quantitative, and
balancing them using a collective expert decision pro-
cess coupled with sensitivity analyses, can reveal new
insights and provide information for guiding prescrib-
ers, policy makers and patients to complement and
augment that available from RCT data. The MCDA
process is particularly pertinent to areas such as CBMPs
for CNP, where, due to the psychoactivity of cannabis,
it is challenging to achieve true blinding in RCTs, and
where the real-world use of CBMPs has continued to
advance rapidly and controversially, despite a limited
and relatively low-quality RCT evidence base. The
issue of blinding has been specifically addressed with
nabiximols with positive assessment of its validity due
to flavoring and low dosing avoiding overt psychoactive
adverse events.30
Methods
Experts ranging from pain clinicians with and without
prescribing expertise in CBMPs from the United King-
dom, Denmark, Israel, and Germany, psychiatrists, a
neurologist, researchers with expertise in cannabinoid
pharmacology, decision analysis, and patient represen-
tatives with personal experience of CBMPs (represent-
ing the United Patients Alliance) were selected and
invited to take part in the MCDA modeling process.
The meeting was facilitated by L.D.P. with support
from D.J.N., but neither of them participated in the
scoring. Participants did not benefit financially from
participating in the MCDA.
A subgroup met on December 9, 2019 to begin the pro-
cess of developing the MCDA model, which would enable
participants in the subsequent ( January 2020) decision
conference to complete their work in 1 day. The subgroup
suggested that the medical condition should be chronic
pain and they developed a list of drugs, including
CBMPs, used to treat chronic pain. They also identified
favorable and unfavorable effects of all treatments and
suggested definitions of all these effects. This preliminary
overview of an MCDA model’s structure was sent to all
participants before the decision conference.
A decision conference is a facilitated workshop31
designed to resolve one or more issues of concern by
building a quantitative model that incorporates the
differing perspectives of the participants along with
data and judgments about the relevance of the data
to those issues of concern.32 At the decision conference,
participants agreed that the potential for orally admin-
istered cannabis-based medicinal products to treat
CNP lasting > 3 months in adults, rather than the
broader ‘‘chronic pain’’ definition, was a key issue
largely because there is more published evidence for
cannabis-based medicinal products alone or in com-
parison with other approved medicines for CNP than
that exists for other pain syndromes.
The process of extending and developing the model
at the decision conference followed the steps developed
during the 2009–2011 Benefit–Risk Project sponsored
by the European Medicines Agency (EMA)33 and by the
2009–2013 IMI-PROTECT administered by the EMA.34
The steps are fully described in Chapter 5 of Benefit–
Risk Assessment in Pharmaceutical Research and Devel-
opment,35 and follow the subheadings hereunder.
Effects and their definitions
At the decision conference, participants reviewed the
subgroup’s benefits and safety effects of medical treat-
ments for CNP. They agreed that pain relief and quality
of life were the two benefits, and they added seven more
safety effects. These are shown in the Effects Tree of
Figure 1, which was created using Hiview3 software,36
with agreed definitions in Table 1.
Treatment options
The group considered 12 pharmacotherapies that are
widely used in chronic pain syndromes. Three differ-
ent types of CBMPs were distinguished: 1:1 ratio
D9—tetrahydrocannabinol (THC): cannabidiol (CBD)
products (e.g., Sativex or 1:1 THC:CBD extracts),
CBD-dominant products (either purified CBD or a
CBD-rich extract with very low or no THC) and
THC-dominant products (either purified THC or a
THC-rich extract with i.e., with very low or no CBD),
administered orally or by sublingual routes. We chose
to consider orally administered pharmacotherapies
only, and not to include inhalation therapies (although
the most commonly used) because of expert recom-
mendations against smoking19 and health concerns re-
lating to other methods of inhalation.
1 THC/CBD 1:1 7 Tramadol
2 CBD dominant 8 Ibuprofen
3 THC dominant 9 Methadone
4 Duloxetine 10 Oxycodone
5 Gabapentinoids 11 Morphine
6 Amitriptyline 12 Fentanyl
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Scoring the drugs on the criteria
Participants evaluated the pharmacotherapies relative
to each other on 0–100 scales, one scale for each effect
criterion, similar to the one for pain relief shown in
Figure 2. First, the group agreed which options were
most preferred for their clinical value, and these were
assigned an arbitrary score of 100. Second, they agreed
the least preferred and assigned it a score of zero. Third,
the group discussed, debated, and agreed scores be-
tween 0 and 100 for the remaining options. All
FIG. 1. The Effects Tree for assessing the relative benefit–safety of neuropathic pain pharmacotherapy.
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numbers represent the judged strength of preference
for the pharmacotherapies; higher numbers represent-
ing more effectiveness for the favorable effects, and bet-
ter safety for the unfavorable effects.
The properties of these 0–100 scales are similar to
those of a Celsius scale, whose 0 and 100 points are
based on the freezing and boiling points of water at
sea level. Zero does not represent no temperature and
100 is not a maximum temperature; the zero for ibu-
profen simply means it has the least effect on pain con-
trol, whereas the three pharmacotherapies at 100 are
tied for having the best effect.
In scoring the options, participants were given a few
moments to think of an appropriate number, com-
pared with the zero and 100, then to say what they
thought, followed by group discussion. This ‘‘think,
reveal, discuss’’ process was intended to prevent partic-
ipants from anchoring on the first person to suggest a
number in open discussion,37 an approach that mini-
mizes bias in group assessments.
Consistency checks initiated by the facilitator were
intended to ensure the internal consistency in the pref-
erence values assessed by the group. For example, the
facilitator asked, ‘‘Morphine has been scored at 50,
duloxetine at 100 and ibuprofen at 0 for pain relief.
Is duloxetine really as much better than morphine as
ibuprofen is worse?’’ This sort of question helps asses-
sors to provide realistic numbers. It also avoids inter-
preting ratios of numbers. Duloxetine is not twice
better than morphine for pain relief because ibuprofen
can provide some pain relief to some patients, so its
zero is merely defining a point on a relative scale, sim-
ilar to zero degrees in Celsius temperature (Table 2).
Weighting the effect criteria
The scoring process resulted in 17 0–100 scales, one for
each effect criterion, but it is evident that not all scales
represent the same ranges of added clinical value, so
Table 1. Definitions of the Favorable and Unfavorable Effects
Effect Description
Favorable effects Pain relief Proportion of patients reporting > 30% reduction in neuropathic pain relief compared with
baseline
Opioid sparing Meaningful reduction in milligrams of 24-h morphine consumption
Quality of life Improvement in quality-of-life score
Unfavorable effects
Adverse events
Psychotomimetic Proportion of patients experiencing psychotomimetic effects
Cognitive impairment Proportion of patients experiencing cognitive impairment
Tolerance increase Proportion of patients requiring more drug as tolerance increases
Dizziness Proportion of patients experiencing dizziness
Drowsy Proportion of patients experiencing drowsiness
Constipation Proportion of patients experiencing constipation
Affect disorders Proportion of patients experiencing affect disorders. Includes anxiety, depression, emotional
blunting, decreased motivation, and disconnect
Unfavorable effects
Serious adverse events
Overdose toxicity The potential for toxic effects from accidental of deliberate overdosing
Cardiac effects Proportion of patients experiencing cardiac effect
Respiratory depression Proportion of patients experiencing respiratory depression
Renal impairment Proportion of patients experiencing renal impairments
Withdrawal Proportion of patients experiencing drug withdrawal per se
Metabolic effects Proportion of patients experiencing metabolic effects. Includes hypoglycemic effects,
diabetics, weight changes, libido, and osteoporosis.
Gastrointestinal Proportion of patients experiencing gastrointestinal effects. Includes bleeds and ulcers.
Dependency The likelihood of increasing the dosage
FIG. 2. Scores agreed by participants for pain
relief.
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participants in the decision conference assigned
weights to each. These are scale constants that equate
the units of preference value across the scales. This
weighting process is analogous to recognizing that
both Fahrenheit and Celsius scales contain 0–100 por-
tions, but the swing in temperature on the Celsius scale
is a greater range of temperature: it takes 9 Fahrenheit
degrees to equal 5 Celsius degrees, a ratio of 9:5.
In MCDA, the process is called ‘‘swing weighting’’ be-
cause it compares the swing from least to most preferred
positions on one scale compared with another.38 It is not
just the importance of the effect, rather it represents
both the objective difference between least and most
preferred positions on a scale, and how much the asses-
sors care about that difference, which usually means
judging the clinical relevance of the difference. The
weighting process went through three stages: (1) relative
weighting of the criteria for the benefit effects, (2) rela-
tive weighting comparing swings for the adverse safety
effects, then for the serious adverse effects, and (3) rela-
tive weighting of the highest-weighted benefit effect
against the highest-weighted safety effect.
The weighting process in MCDA preserves the ratios
of all weights even though they are eventually normal-
ized to ensure they sum to 1.00 (displayed in this report
as 100) across all the criteria before multiplying by the
scores to give the final weighted preference values. The
group judged the clinical difference between the best
and worst drug for quality of life to be the largest dif-
ference for this set of drugs, with pain relief the second
largest best–worst difference.
Results
Multiplying preference values by the corresponding
swing weights and summing those products for each
drug gives the overall weighted preference values
shown in Table 3. The figures in the white rows are
now referred to as benefits and safety because they rep-
resent the weighted input evaluations separately for the
two benefits and the 15 safety effects. The bottom total
row shows the weighted average of the two weighted
sums in each column, providing a single figure that
represents each drug’s benefit–risk balance. For exam-
ple, the equation for THC/CBD is simply (81 · 0.352) +
(78 · 0.648) = 79. Figure 3 shows bar graphs of the sepa-
rate weighted benefits and safety.
The breakdown of the weighted benefit and risks
is shown in Figure 4, with a separate color associated
with each of the 17 effect criteria. The figure is based




























































































































































































































































































































































































































































































































































































6 NUTT ET AL.
This final table, called an Effects Table, provides
the information for comparing the effects for any
of the drugs as the weighting process has provided
a common unit of preference value. Recall that only
differences between the weighted preference values
and/or their totals can be compared meaningfully,
not their ratios.
Trade-offs between benefits and safety
At this point it would be useful to see the separate
weighted preference values for the benefits and for
the safety effects without regard for the trade-off weight
between those two nodes. This is shown in Figure 5.
The circles are located at the values of benefits and
safety from the corresponding rows of Table 3.
The ideal position on this graph would be the upper
right, a beneficial safe pharmacotherapy, scoring 100
and 100, but there is no drug that is best in overall benefits
and safety. THC/CBD is the best compromise between the
higher benefits but less safety of THC, on the one hand, or
the safer but lesser benefits of CBD, on the other hand.
Those three drugs define what is known as the ‘‘effi-
cient frontier;’’ there is no better drug outside the blue
shading. However, close examination reveals a unique
feature: THC/CBD and THC are better in benefits and
safety than all the noncannabinoid pharmacotherapies.
The only exception is ibuprofen, whose safety score is
79 compared with 78 for THC/CBD. For all the other
noncannabinoids, at least one of the three CBMPs is bet-
ter. If a regression line were fit through the noncannabi-
noids, excepting ibuprofen, it would be tilted from lower
left to upper right, which shows a trend for delivering
more benefit at greater safety, an interesting feature.
Sensitivity analyses
Some participants were surprised to see the CBMPs
dominating the other drugs and requested that sensi-
tivity analyses be performed to address any potential
bias (or perceived bias) in the group’s scores and
weights. These sensitivity analyses involved making
changes to the inputs, both during and after the deci-
sion conference, to demonstrate the extent to which re-
sults would change with different scores or weights.
Changes in the weights were explored for all the ef-
fect criteria and the nodes in the Effect Tree. Nearly all
showed that the dominance of the CBMPs remained,
although not necessarily as strongly, over plausible
ranges for weights. The only effect that breaks the dom-
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FIG. 3. The overall weighted preference values for the neuropathic pain pharmacotherapies. More blue
means more benefit, more red indicates more safety.
FIG. 4. Contributions to the totals by each of the 17 effects. The top blue (pain relief) and yellow (quality
of life) sections of each bar show the magnitude of benefits; the rest show safety.
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The vertical red line is located at the current weight
for pain relief, 14.5 (from Fig. 3). All the other lines
represent their total score as the weight on pain relief
is changed. The intersection of the vertical red line
with each of the other lines occurs at their total values
shown in Table 3. As the weight is increased, THC/
CBD declines in preference, with duloxetine emerging as
better when the weight exceeds 35, followed closely by
the gabapentinoids and amitriptyline, then opioids.
After the decision conference, one participant sug-
gested we had scored THC/CBD and THC too high
on pain relief and quality of life and suggested those
two scores be decreased by half. The result is shown
in the benefit versus safety plot of Figure 7.
Halving just the pain control scores shows that
THC/CBD and THC still dominate the pharma-
cotherapies, but less so than shown in Figure 5. In
addition, if the quality-of-life scores for the two canna-
binoids are halved, the right plot shows that duloxetine
and the gabapentinoids move up to the efficient fron-
tier, with amitriptyline slightly less good.
Differences
The aforementioned plots made no assumption about
the trade-off between benefits and safety. Taking ac-
count of that trade-off makes it possible to compare
the performance between pharmacotherapies because
the scores are based on a common unit of preference
value. The aforementioned analyses show that decisions
about the drug will be different depending on whether a
patient or clinician is more concerned about pain relief
or about quality of life, as seen most clearly in Figure 8.
The weighted difference (Wtd Diff) column shows the
result of multiplying the cumulative weight (Cum Wt) for
each effect by the difference in preference values (Diff)
between the two drugs shown in the top white fields.
The effects have been put in order of the Wtd Diffs of
the pair of pharmacotherapies, with the Wtd Diff sum
equal to the difference in their overall preference values
(negative signs favor the right-listed pharmacotherapies
over the left one). The green horizontal bar graphs
show the relative advantages of THC:CBD, and the red
bars are the advantages of duloxetine. The sums of
those positive and negative weighted scores equals the
15-point difference in their total scores shown in Table 3.
Discussion
This is the first time that CBMPs have been subjected
to an MCDA and compared with each other and































































































































































































































































































































































































































































































































































































































































































MCDA COMPARING PHARMACOTHERAPY FOR PAIN 9
FIG. 5. Benefit preference values versus the safety preference values shown in Table 3.
FIG. 6. Sensitivity analysis for pain relief.
10
FIG. 7. The results of sensitivity analyses on the input preference scores for THC/CBD and THC. Halving
the Pain Control scores gives the left plot. An additional halving of the quality-of-life scores is shown in the
right plot. CBD, cannabidiol; THC, tetrahydrocannabinol.
FIG. 8. THC/CBD is better for quality of life, but duloxetine is better for pain relief. This pattern is similar
for gabapentinoids and amitriptyline as comparators with THC/CBD.
11
benefit–safety balances. In this study, we compared three
cannabinoid options and nine noncannabinoid medica-
tions for their beneficial effects on pain relief and quality
of life, against seven adverse effects, and eight serious ad-
verse effects. The results showed the best benefit–safety
balance, 79, for THC/CBD (1:1), and least good balance
for fentanyl, 33. The 46-point difference in performance
is substantial, with about two-thirds of the difference
contributed by better quality of life and lack of overdose
toxicity and respiratory depression.
The dominance analysis showed that two CBMPs op-
tions, THC/CBD and THC, are more beneficial and safer
than any of the alternatives. However, that generaliza-
tion is only valid at the level of the combined benefits
and combined safety effects. The Effects Table at
Figure 4 gives the weighted preference values for all
204 combinations of the 12 pharmacotherapies and 17
effects. The table shows duloxetine, gabapentinoids,
and amitriptyline as best for pain relief, with THC/CBD
and THC as best for quality of life. The Effects Table also
highlights the worst side effect for each drug. Only
THC/CBD, CBD, and duloxetine avoid worst scores
for side effects, whereas THC has only one worst score,
for psychotomimetic effects.
Sensitivity analyses—conducted jointly during the
MCDA process—helped to resolve uncertainty about
the data, such as it is, and disagreements about weights.
Fortunately, MCDA models are fairly robust to impre-
cision in the inputs,39 which was borne out for this
MCDA on CBMPs The benefit versus safety graphs
showed that THC/CBD remained the most preferred
pharmacotherapy over wide ranges of weights on the
safety node and the individual effects. Since this
emerged from a multitude of questions and compar-
isons, rather than straightforward simple scoring,
the final dominance at the benefit–safety level of
the cannabinoids over all the other medicines was
initially surprising to the group. However, this be-
came reasonable and accepted by the group in light
of the recognition that CBMPs scores were driven
by their beneficial effects on quality of life, combined
with their superior side effects profile. The 15-point
superiority of THC/CBD over duloxetine, for exam-
ple, was due to better quality of life, less overdose
toxicity, cognitive impairment, and less disturbance
on affect, which provided a net benefit for the CBMPs
over duloxetine’s better pain relief and psychotomi-
metic effects. This profile was similar to the differ-
ence between THC/CBD and gabapentinoids and
amitriptyline.
Many pain patients seek medical attention precisely
because their pain interferes with some or all aspects of
their quality of life.40 Simple pain scores, although pro-
viding important information, do not capture the pa-
tient’s total pain experience, which includes the effect
on quality of life.41 In our study, the improvement in
quality of life was considered a major therapeutic target
by the two patient representatives a view supported by
the expert clinicians within the group and by the re-
search of Almeida et al.42
This complex multimodal analgesia exerted by THC
is compatible with the ubiquitous distribution of CB1 re-
ceptors in the CNS and the fact that cannabinoids act as
complex neuromodulators. It has also been shown that
the analgesic effects of THC may be more attributable
to its effects on higher cognitive emotional brain mech-
anisms than its effects on somatosensory processing
(antinociception).43 Clinically, this has been scarcely ex-
plored. In one of the two medical cannabis studies in-
cluding quality of life, Toth et al.44 highlight that
flexible-dose nabilone (1–4 mg/day) was effective in re-
lieving neuropathic pain symptoms, improving dis-
turbed sleep, and overall quality of life. In another
small study of 23 participants, Ware et al.45 found no
statistically significant effects on quality of life of smok-
ing cannabis with THC potencies of 0%, 2.5%, and 6%.
However, at 9.4% sleep improved. The absence of qual-
ity research on quality-of-life studies is disappointing
and highlights the need to collect better evidence.
Recognizing the relative paucity of high-quality
published data on the three cannabinoid pharmaco-
therapies, the group conducted a sensitivity analysis
whereby scores on pain relief for THC/CBD and
THC were halved; but these two cannabinoids still
dominated the alternatives. In contrast, when the input
preference scores on quality of life were also halved,
then duloxetine, the gabapentinoids, and amitriptyline
clustered together near or on the efficient curve, leav-
ing the CBMPs well inside.
The Effects Table provides the collective views of the
experts, clinicians, and patients who participated in the
decision conference, so could be of use to a prescriber
wishing to make a better-informed decision for an in-
dividual patient. As a general example, if a patient
and their clinician are more concerned about quality
of life than pain relief, then Table 4 shows that
THC/CBD or THC could be the best pharmacother-
apy. For patients who are more concerned about pain
relief, then duloxetine might be the best choice, as it
has a better safety profile than the gabapentinoids
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and amitriptyline. The Effects Table makes clear that
there is a trade-off to be considered between pain relief
and quality of life measures, and that side effect profiles
need to be considered. The Effects Table makes all this
explicit in a form made possible by MCDA modeling.
The data supplied regarding subscores may, therefore,
further serve to consider specific desired or undesired
effects in patients with specific symptom constellations
and/or medical comorbidities.
A main limitation of this study is in the shortage of
published data for some of the pharmacotherapies, par-
ticularly for the CBMPs (and CBD alone in particular),
requiring heavy reliance on participants’ judgments
about scores. That paucity of data was not only antici-
pated but was actually the rationale for holding this
MCDA meeting and benefitting from the real-world
views of an expert panel. Accordingly, participants
were carefully chosen for their medical and scientific
expertise about neuropathic pain and its treatment,
clinical experience in treating patients, knowledge
about cannabinoids and CBMPs, and incorporating
representatives of patients with CNP who have direct
experience themselves with the pharmacotherapies
reviewed and were also acquainted with the experi-
ences of other patients using them.
At the end of the decision conference, participants
were asked for their views of the MCDA/decision con-
ferencing approach. Most considered the results were a
very good way of reaching a joint result about an issue
for which there is little data. Several participants
thought the group might be biased in favor of the
CBMPs. Some participants also thought the group
might be biased against opioids although they are
widely used (although not usually guideline recom-
mended) in treatment of CNP. It was felt that this
may have been particularly influenced by the patient
representatives’ opinions expressing negative views.
Bias is indeed a concern in any study relying on re-
sponses from panel members. Fortunately, minimizing
or eliminating bias is built into the decision conferenc-
ing process by careful selection of participants with di-
verse views on the key issues and the application by the
facilitator of bias-minimizing techniques in eliciting
participants’ judgments, as had been explained else-
where.46,47 We would welcome studies aiming to repli-
cate this research with different groups of experts in
different countries. Finally, although we fully ac-
knowledge that this MCDA approach is not a substi-
tute for high-quality clinical trials, it may serve to
responsibly share valuable clinical experience, and
provide much-needed guidance to prescribers and pa-
tients while awaiting publications of better evidence in
the field.
Conclusions
What is known about this topic
The value of CBMPs for pain management remains con-
troversial. Some patients and clinicians prefer it to other
medications but in the United Kingdom most doctors
are reluctant to prescribe because high-quality evidence-
based recommendations are lacking, and clinical experi-
ence, education, and support are limited. In the absence
of persuasive evidence, and in the face of growing clin-
ical use, it is important to obtain the best specialist esti-
mates of the value of the available cannabis-based
medicinal products. This is ideally performed by apply-
ing MCDA using evidence from RCTs and judgments
about the clinical relevance of the evidence to determine
the benefit–safety balance of drugs.48
What this study has contributed
Our study, the first of its kind, revealed clinically relevant
differences in efficacy and adverse effects ratings for a
range of different pharmacotherapies used for neuro-
pathic pain. Overall CBMPs of THC/CBD, in a 1:1
ratio, achieved the highest overall score, followed by
CBD dominant at 75, then THC dominant at 72. When
only benefit measures are considered and not safety mea-
sures, the antidepressants (duloxetine and amitriptyline)
and the gabapentinoids were rated best for pain control,
whereas the THC-containing products scored best for im-
proving quality of life. When safety benefits alone were
considered CBD/ibuprofen and THC/CBD came out best.
The current disparity between prescribers’ and pa-
tients’ beliefs in CBMPs medical cannabis may reflect
different weightings being given to the relief of pain
compared with quality of life. The impact of CBMPs on
improving patients’ quality of life is increasingly recog-
nized.49,50 As it emerges that cannabinoids are relatively
safe options, certainly compared with other substances
used for CNP management, they should be included in
the armamentarium of clinical specialists, in line with
the recent position article from the European Pain Feder-
ation Task Force on the topic.19 The decision regarding
specific patients should take into account existing litera-
ture and professional guidelines and, in the face of partial
evidence, collective clinical experience. This option
should be patient tailored, that is, explored in detail by
prescribers and patients together when pharmacological
treatment of neuropathic pain is being considered.
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CBMPs¼ cannabis-based medical products
CI¼ confidence interval
CMC¼Centre for Medical Cannabis
CNP¼ chronic neuropathic pain
DDS¼descriptor differential scale
DPN¼diabetic peripheral neuropathy




NASEM¼National Academies of Sciences, Engineering and Medicine
NNT¼number needed to treat
NRS¼numerical rating scale
PNP¼peripheral neuropathic pain
RCT¼ randomized control trial
SAEs¼ serious adverse events
SGIC¼ Subject Global Impression of Change
THC/CBD¼ tetrahydrocannabinol/cannabidiol
VAS¼ visual analog scale
(Appendix follows /)
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